scholarly journals Evaluation of hypoglycemic effect, safety and immunomodulation of Prevotella copri in mice

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Phebe Verbrugghe ◽  
Jón Brynjólfsson ◽  
Xingjun Jing ◽  
Inger Björck ◽  
Frida Hållenius ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Systemic Infection ◽  
Serum Levels ◽  
Parameter Analysis ◽  
Hypoglycemic Effect ◽  
Haematological Parameter ◽  
Oral Toxicity ◽  
Glucose Levels ◽  
Healthy Humans ◽  
Cytokine Analysis

AbstractThe gut bacterium Prevotella copri (P. copri) has been shown to lower blood glucose levels in mice as well as in healthy humans, and is a promising candidate for a next generation probiotic aiming at prevention or treatment of obesity and type 2 diabetes. In this study the hypoglycemic effect of live P. copri was confirmed in mice and pasteurization of P. copri was shown to further enhance its capacity to improve glucose tolerance. The safety of live and pasteurized P. copri was evaluated by a 29-day oral toxicity study in mice. P. copri did not induce any adverse effects on body growth. General examination of the mice, gross pathological and histological analysis showed no abnormalities of the vital organs. Though relative liver weights were lower in the pasteurized (4.574 g ± 0.096) and live (4.347 g ± 0.197) P. copri fed groups than in the control mice (5.005 g ± 0.103) (p = 0.0441 and p = 0.0147 respectively), no liver biochemical marker aberrations were detected. Creatinine serum levels were significantly lower in mice fed with live (p = 0.001) but not pasteurized (p = 0.163) P. copri compared to those of control mice. Haematological parameter analysis and low plasma Lipopolysaccharide Binding Protein (LBP) levels ruled out systemic infection and inflammation. Immunomodulation capacity by P. copri as determined by blood plasma cytokine analysis was limited and gut colonisation occurred in only one of the 10 mice tested. Taken together, no major adverse effects were detected in P. copri treated groups compared to controls.

PENGARUH PEMBERIAN FRAKSI ETILASETAT KULIT UBI JALAR UNGU TERHADAP KADAR MALONDIALDEHID (MDA) SERUM MENCIT PUTIH JANTAN HIPERGLIKEMIA

2018 ◽  
Vol 8 (2) ◽  
pp. 144
Author(s):  
Ria Afrianti
Keyword(s):  
Blood Glucose ◽  
Statistical Analysis ◽  
Sweet Potato ◽  
Ethyl Acetate Fraction ◽  
Serum Levels ◽  
Negative Control ◽  
Control Group ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Purple Sweet Potato

This study aims to determine the effect giving of ethylacetate fraction of leather  purple sweet potato (Ipomoea batatas (L.) Lam, on levels of malondialdehyde (MDA) serum in mice hyperglicemia were induced with streptozocin dose of 50 mg/kgBW. Mice were divided into 5 groups, each group consisting of 3 tails, group I is a negative control, group II is a positive control, group III,IV and V is given ethylacetate fraction a dose of 100 mg/kgBW, 300 mg/kgBW, and 600 mg/kgBW. Ethyl Acetate Fraction leather purple sweet potato given orally for 15 days after the animal is declared hyperglicemia and measurement of blood glucose levels on 5, 10, and 15 day after giving test preparation in animal experiments. On the 16 day throughout the mice were taken serum levels measured malondialdehid. The statistical analysis results showed that giving of ethyl acetate fraction of leather purple sweet potato at a dose of 100 mg/kgBW, 300 mg/kgBW, and 600 mg/kgBW can lower blood glucose levels in mice hyperglycemia significantly (p<0.05). Malondialdehid levels on average in each group is 1.35 nmol/ml, 3.00 nmol/ml, 2.72 nmol/ml, 2.20 nmol/ml and 2.61 nmol/ml, the results of statistical analysis showed a decrease in melondialdehid serum levels were significantly (p<0.05), where a dose of 300 mg/kgBW is an effective dose for lowering blood glucose levels followed by decreased levels of malondialdehid which give effect approaching negative control.

Cytokine analysis in patients with different stages of thromboangiitis obliterans

2020 ◽  
Vol 20 ◽  
Author(s):  
Abbas Shapouri-Moghaddam ◽  
Seyed Jalil Tavakkol Afshari ◽  
Mohammad-Hadi Saeed Modaghegh ◽  
Hamid Reza Rahimi ◽  
Mahmoud Mahmoudi ◽  
...  
Keyword(s):  
Transforming Growth Factor ◽  
Vascular Diseases ◽  
Transforming Growth Factor Β ◽  
Serum Levels ◽  
Interferon Γ ◽  
Analysis Of Covariance ◽  
Cold Sensitivity ◽  
Thromboangiitis Obliterans ◽  
Burning Pain ◽  
Cytokine Analysis

Background: Studies suggest that cytokines are involved in the development of both inflammatory disorders and vascular diseases. Objective: The changes in transforming growth factor β (TGFβ), interleukin 6 (IL6), tumor necrosis factor α (TNFα), and interferon γ (IFNγ) with the progression of the thromboangiitis obliterans (TAO) symptomswereinvestigated in this research. Methods: This study included 80 patients with TAO, who were selected from the Vascular and Endovascular Research Center in Alavi Hospital between 2012 and 2016. They were then categorized into three groups: mild (migratory thrombophlebitis, cold sensitivity or Raynaud's phenomenon, and skin discoloration), moderate (chronic ulcers, claudication, and burning pain of the feet at night), and severe (pain at rest and spontaneous gangrene) symptoms. The serum levels of TGFβ, IL6, TNFα, and IFNγwere determinedby the ELISA method and compared among the groups. Results: The first three predominant symptoms were pulse disorder (n = 76, 95.00%), cold intolerance (n = 61, 76.25%), and claudication (n = 59, 73.75%). A comparison of the analysis of covariance (ANCOVA) revealed that both TGFβ and IL6 were dysregulatedas the severity of the symptoms increased from the moderate to the severe stages; however, such changes were not significant(p > 0.05). In the multiple logistic regression model, increased TNFαlevelswere seen in the presence of the moderatesymptoms as compared to the severe ones (p < 0.05). Conclusion: It could be concluded that TNFα, as part of the defining cytokine-production profile of Thelper cells, can be significantly involved in the progression of TAO from the moderate to the severe stages.

scholarly journals Salmonella Typhimurium reprograms macrophage metabolism via T3SS effector SopE2 to promote intracellular replication and virulence

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Lingyan Jiang ◽  
Peisheng Wang ◽  
Xiaorui Song ◽  
Huan Zhang ◽  
Shuangshuang Ma ◽  
...  
Keyword(s):  
Carbon Sources ◽  
Systemic Infection ◽  
Pathogenicity Island ◽  
Intracellular Replication ◽  
Glucose Levels ◽  
T3ss Effector ◽  
Glycolytic Intermediates ◽  
Bacterial Uptake ◽  
Lactate Levels ◽  
Host Metabolism

AbstractSalmonella Typhimurium establishes systemic infection by replicating in host macrophages. Here we show that macrophages infected with S. Typhimurium exhibit upregulated glycolysis and decreased serine synthesis, leading to accumulation of glycolytic intermediates. The effects on serine synthesis are mediated by bacterial protein SopE2, a type III secretion system (T3SS) effector encoded in pathogenicity island SPI-1. The changes in host metabolism promote intracellular replication of S. Typhimurium via two mechanisms: decreased glucose levels lead to upregulated bacterial uptake of 2- and 3-phosphoglycerate and phosphoenolpyruvate (carbon sources), while increased pyruvate and lactate levels induce upregulation of another pathogenicity island, SPI-2, known to encode virulence factors. Pharmacological or genetic inhibition of host glycolysis, activation of host serine synthesis, or deletion of either the bacterial transport or signal sensor systems for those host glycolytic intermediates impairs S. Typhimurium replication or virulence.

scholarly journals Adverse outcome of methotrexate and mini pulse betamethasone in the treatment of lichen planus

2013 ◽  
Vol 39 (1) ◽  
pp. 22-27 ◽  
Author(s):  
SC Hazra ◽  
AM Choudhury ◽  
ATM Asaduzzaman ◽  
HK Paul
Keyword(s):  
Adverse Effects ◽  
Lichen Planus ◽  
Adverse Outcome ◽  
Adverse Outcomes ◽  
Haematological Parameter ◽  
Morning Dose ◽  
Group A ◽  
Laboratory Investigations ◽  
Group B ◽  
Medical University

The objectives of this study were to compare the adverse outcome of methotrexate and mini pulse betamethasone therapy in the treatment of lichen planus. It was a clinical trial conducted in the department of Dermatology and Venereology, Bangabandhu Sheikh Mujib Medical University, Dhaka, from January 2009 to December 2010. Forty four patients of lichen planus were included in the study. Patients in Group-A, (n=23) were treated with methotrexate (10 mg) single morning dose and group-B (n=21) were treated with mini pulse betamethasone (5mg) single morning dose on 2 consecutive days during the period of 12 weeks. Adverse outcomes were measured by clinical examination and laboratory investigations during follow up visits. Anemia 3(14.2%) and edema 12(57.1%) developed in group-B but none in group-A. In group-B, dyspepsia 15(71.4%), acne 10(47.6%), mooning face 8(38.1%), striae 8(38.1%) and hypertrichosis 4(19.0%) developed but none in group-A. Intermittent diarrhoea, headache, nausea and fatigue complained in both groups of patients but the percentage of complaints was higher amog group-B compared to group-A. Menstrual abnormality developed in group-B 5(71.4%) but none in group-A. Laboratory investigations showed abnormality in platelet count and SGPT in group-A but none in group-B. The adverse effects of methotrexate on haematological parameter and liver functions were mild and could be prevented by reducing the dose but the adverse effects of betamethasone were unavoidable. The overall adverse effects were less in group-A than group-B. Therefore, methotrexate can be used as an alternative safer option for the treatment of lichen planus. DOI: http://dx.doi.org/10.3329/bmrcb.v39i1.15806 Bangladesh Med Res Counc Bull 2013; 39: 22-27

Final Report on the Safety Assessment of Polyacrylamide

1991 ◽  
Vol 10 (1) ◽  
pp. 193-203 ◽  
Keyword(s):  
Body Weight ◽  
Adverse Effects ◽  
Safety Assessment ◽  
Maximum Dose ◽  
Toxicity Study ◽  
Final Report ◽  
Oral Toxicity ◽  
Monomer Content ◽  
Acrylamide Monomers ◽  
Reproductive Study

Polyacrylamide is a polymer of controllable molecular weight formed from the polymerization of acrylamide monomers. Average concentrations of the monomer were reported as less than 0.01% by several manufacturers. Polyacrylamide is used as a foam builder and stabilizer in shampoo products and as a vehicle in sunscreen preparations. An acute oral toxicity study of Polyacrylamide in rats reported that a single maximum oral dose of 4.0 g/kg body weight was tolerated. In a subchronic oral toxicity study in both rats and dogs, animals were given a maximum dose of 464 mg/kg body weight, with no signs of toxicity in any animals. Two separate studies in rats reported no absorption when the compound was administered by gavage. In a 2-year chronic oral toxicity study, rats fed between 500 and 10,000 ppm in their diet had no significant adverse effects. Similar results were obtained in dogs. A 2-year feeding study in rats fed up to 5.0% Polyacrylamide reported no significant adverse effects. Cutaneous tolerance tests performed to evaluate the irritation of Polyacrylamide indicated that the compound was relatively well tolerated. Undiluted Polyacrylamide applied to the conjunctival sac of the rabbit caused a very slight response. No compound-related lesions were noted in a three-generation reproductive study in which rats were fed either 500 or 2000 ppm Polyacrylamide. On the basis of data presented in this report, it is concluded that Polyacrylamide, with less than 0.01% acrylamide monomer content, is safe as a cosmetic ingredient as currently used.

scholarly journals Effects of 10-Week Concurrent Training on Insulin Resistance and the Serum Levels of Vaspin and Visfatin in Overweight Females

2019 ◽  
Vol 25 (3) ◽  
pp. 146-157
Author(s):  
Abdolreza Kazemi ◽  
◽  
Sareh Mahalati ◽  
Keyword(s):  
Insulin Resistance ◽  
Metabolic Diseases ◽  
Intervention Group ◽  
Serum Levels ◽  
Analysis Of Covariance ◽  
Concurrent Training ◽  
Improve Insulin Sensitivity ◽  
Glucose Levels ◽  
Kerman City ◽  
Training Protocol

Aims: The present study investigated the effects of a 10-week concurrent training on the serum levels of vaspin and visfatin in overweight females. Methods & Materials: Twenty-four over-weight females from Kerman City, Iran (Mean±SD age: 11.23±0.62 years; Mean±SD weight: 64.83±2.70kg; Mean±SD BMI: 27.97±0.47 kg/m2) were randomly assigned into the control and concurrent training groups. The intervention group performed the training protocol as follows: endurance training: 65-85% of Vo2 max for 20 minutes per session, and resistance training: 50-60% of One Repetition Maximum (1RM) for 30 minutes per session and 3 days a week for 10 weeks. Fasting plasma vaspin, visfatin, and insulin levels were measured by ELISA method. To analyze the data, Analysis of Covariance (ANCOVA) was used. Findings: Performing 10 weeks of concurrent training significantly decreased vaspin and visfatin plasma levels, and insulin resistance resting levels (P≤0.05); however, there was no significant decrease in glucose levels. Conclusion: Concurrent training can decrease insulin resistance, probably by reducing vaspin and visfatin in overweight females. Therefore, it is suggested that overweight females use concurrent training to improve insulin sensitivity and prevent metabolic diseases.

scholarly journals Pattern of adverse effects in patients with nephrotic syndrome on oral prednisolone

2017 ◽  
Vol 6 (6) ◽  
pp. 1269
Author(s):  
Shankareswari S. ◽  
Jayapriya B. ◽  
Balamurugan P. V. ◽  
Lourdu Jafrin A. ◽  
Geetha K.
Keyword(s):  
Nephrotic Syndrome ◽  
Adverse Effects ◽  
Short Stature ◽  
Oral Prednisolone ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Glucose Levels ◽  
Long Term Follow Up ◽  
Literature Evidence ◽  
Paediatric Age

Background: Nephrotic syndrome is a common illness affecting the paediatric age group and 80% of the idiopathic syndrome is steroid sensitive. Multiple relapses make them vulnerable to the adverse effects of corticosteroids. There is limited literature evidence for the adverse effects of steroids in children with renal pathology.Methods: This descriptive, cross sectional study analyses the adverse effects of oral prednisolone in children and adults with nephrotic syndrome Fifty-five patients with nephrotic syndrome, attending nephrology or paediatric OP, more than 3 years of age and who were on oral prednisolone for a minimum of eight weeks were included in the study. Demographic details, detailed history, lab investigations and ophthalmic examination were done and the results were analysed.Results: Hypertension and behavioural changes were the most common adverse effects followed by dermatological, endocrine and metabolic changes. Infections and gastrointestinal disturbances were more in adults (p <0.05). Short stature was more in children (p< 0.05). There was no abnormality in blood glucose levels and body weight. Hypertension, cushingoid habitus, infections and short stature were statistically less in patients on alternate day prednisolone. But no statistical association could be made between the occurrence of cataract and the pattern of prednisolone use.Conclusions: Adverse effects pattern is different among adults and children. Also, the adverse effects are less with alternate day prednisolone regimen. Long term follow up into their adulthood is needed to analyse the morbidity produced by corticosteroids in these subsets of population.

scholarly journals Study of Adverse Effect Profile of Zoledronic Acid Infusion Among Patients with Cancer: A Retrospective Analysis

2020 ◽  
Vol 13 (10) ◽  
Author(s):  
Lina Elsalem ◽  
Haneen A. Basheer ◽  
Ayat Alshoh ◽  
Abdullah Abu-Aqoulah ◽  
Hussein Alsa'di ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Adverse Effects ◽  
Biochemical Parameters ◽  
Symptomatic Treatment ◽  
Serum Levels ◽  
Mean Values ◽  
Protein Levels ◽  
Patients With Cancer ◽  
Significant Difference ◽  
Pre Treatment

Background: Zoledronic acid (ZA) is widely used in the management of cancer-related bone events. It, however, might be associated with serious adverse effects. Objectives: To evaluate ZA adverse effects and changes in biochemical parameters related to ZA toxicities among patients with cancer. Methods: Ninety-eight oncology patients, who were prescribed ZA intravenous (IV) infusion, were interviewed to assess whether they experienced ZA related symptoms, including acute events and serious adverse effects. ZA’s effects on the serum levels of different biochemical parameters were retrospectively assessed by checking patients’ electronic medical records. Results: The most commonly reported adverse effects were: myalgia (48%), bone pain (36.7%), influenza-like symptoms (34.7%), headache (31.6%), and pyrexia (22.45%) with decreasing frequency of such adverse effects upon repeated infusions. Serious side effects including jaw osteonecrosis, cardiac, and renal problems were not reported. A small, but statistically significant reduction in serum calcium, creatinine, and total protein levels was observed upon comparing levels before and after the first IV infusion of ZA (P ≤ 0.031). No significant change was recorded with other serum electrolytes including phosphorus, sodium, potassium, and magnesium as well as urea levels (P ≥ 0.271). No significant difference was determined in terms of final serum levels of all parameters in comparison to pre-treatment (P ≥ 0.059), except for potassium, where a significant reduction was observed (P = 0.003). Notably, the mean values of all parameters were within the normal range. Conclusions: ZA acute events resolved with symptomatic treatment and reduced with repeated IV infusions. ZA appears as a safe treatment modality for skeletal-related events among patients with cancer and the reported adverse effects should not affect patients’ compliance.

scholarly journals SODIUM-GLUCOSE LINKED COTRANSPORTER 2 INHIBITOR: A NEW HORIZON IN THE TREATMENT OF TYPE-2 DIABETES

2021 ◽  
pp. 45-48
Author(s):  
REKHA BISHT
Keyword(s):  
Type 2 Diabetes ◽  
Adverse Effects ◽  
Antidiabetic Drugs ◽  
Diabetic Patients ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Sodium Glucose Cotransporter ◽  
Glucose Reabsorption ◽  
Glycemic Targets

Hyperglycemia is a key therapeutic focus in the management of patients with type 2 diabetes (T2D) mellitus. The various therapeutic classes of antidiabetic drugs presently existing in the market are not sufficiently effective in maintaining long-term glycemic control in most of the diabetic patients, even when used in combination. The undesirable adverse effects of these drugs, such as hypoglycemia, weight gain, and hepatic and renal toxicity, have escalated the demand for the discovery of new and safer antidiabetic drugs. The progressive nature of T2D requires practitioners to periodically evaluate patients and intensify glucose-lowering treatment once glycemic targets are not attained. Sodium-glucose cotransporter 2 inhibitors (SGLT2-is) are the new class of antidiabetic medications that are approved (2013) by the Food and Drug Administration recently for treating diabetes. These inhibitors block the SGLT2 protein involved in glucose reabsorption from the proximal renal tubule resulting in escalated glucose excretion and lower blood glucose levels. These inhibitors exhibit favorable effects beyond glucose control, such as consistent body weight, blood pressure, and serum uric acid reductions. This review highlighted the brief updates of SGLT2-i, their benefits, and adverse effects.

Influence of Metabolic Syndrome on Factors Associated with Chronic Kidney Disease: A Cross-Sectional Study

2021 ◽  
Vol 17 ◽  
Author(s):  
Camila Santos Marreiros ◽  
Thaís Rodrigues Nogueira ◽  
Paulo Pedro do Nascimento ◽  
Diana Stefany Cardoso de Araújo ◽  
Nayara Vieira do Nascimento Monteiro ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Serum Levels ◽  
Cross Sectional Study ◽  
Serum Glucose ◽  
Cross Sectional ◽  
Significance Level ◽  
Glucose Levels ◽  
Progression Of Kidney Disease

Background: Metabolic Syndrome (MetS) is defined by the presence of three or more of the following components: inadequate fasting serum glucose levels and elevated waist circumference, hypertension and dyslipidemia, which represent a potential risk for the development and/or worsening of Chronic Kidney Disease. Objective: This research aimed to investigate the presence of MetS and its influence on associated factors in patients with Chronic Kidney Disease undergoing hemodialysis. Methods: This is an evaluation of a cross-sectional multicenter research project, carried out with 95 patients with Chronic Kidney Disease, seen at outpatient clinics in the state capital Piaui. Anthropometric, biochemical and hemodynamic parameters were determined. The data were analyzed using the Stata® v.12 software (Statacorp, College Station, Texas, USA), adopting a significance level of p < 0,05. The survey received ethical approval (nº 2.527.329). Results: It was observed that individuals with elevated BMI, WC, NC, SBP, DBP were more likely to develop MetS, with significant differences (p <0.001). In addition, it was found that serum levels of glucose, insulin, HOMA-IR, TC, LDL, TG and blood pressure were higher in the group with MetS. Conclusion: It was concluded that changes in the parameters analyzed in patients with CKD reinforce MetS as a predictive condition for worsening nutritional status and a factor for the progression of kidney disease.

Sign in / Sign up

Export Citation Format

Share Document